|
Name |
Martinoside
|
Molecular Formula | C31H40O15 | |
IUPAC Name* |
[(2R,3R,4S,5R,6R)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[(2S,3R,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
|
|
SMILES |
C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)OC)CO)OCCC4=CC(=C(C=C4)OC)O)O)O)O)O
|
|
InChI |
InChI=1S/C31H40O15/c1-15-24(36)25(37)26(38)31(43-15)46-29-27(39)30(42-11-10-17-5-8-20(40-2)19(34)12-17)44-22(14-32)28(29)45-23(35)9-6-16-4-7-18(33)21(13-16)41-3/h4-9,12-13,15,22,24-34,36-39H,10-11,14H2,1-3H3/b9-6+/t15-,22+,24+,25+,26+,27+,28+,29-,30+,31-/m0/s1
|
|
InChIKey |
WLWAYPFRKDSFCL-PAQNRFGGSA-N
|
|
Synonyms |
martinoside
|
|
CAS | NA | |
PubChem CID | 13989933 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 652.6 | ALogp: | 0.1 |
HBD: | 7 | HBA: | 15 |
Rotatable Bonds: | 13 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 223.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 46 | QED Weighted: | 0.119 |
Caco-2 Permeability: | -6.461 | MDCK Permeability: | 0.00005340 |
Pgp-inhibitor: | 0.039 | Pgp-substrate: | 0.996 |
Human Intestinal Absorption (HIA): | 0.958 | 20% Bioavailability (F20%): | 0.039 |
30% Bioavailability (F30%): | 0.999 |
Blood-Brain-Barrier Penetration (BBB): | 0.064 | Plasma Protein Binding (PPB): | 95.81% |
Volume Distribution (VD): | 0.36 | Fu: | 6.28% |
CYP1A2-inhibitor: | 0.048 | CYP1A2-substrate: | 0.134 |
CYP2C19-inhibitor: | 0.07 | CYP2C19-substrate: | 0.244 |
CYP2C9-inhibitor: | 0.064 | CYP2C9-substrate: | 0.295 |
CYP2D6-inhibitor: | 0.024 | CYP2D6-substrate: | 0.227 |
CYP3A4-inhibitor: | 0.089 | CYP3A4-substrate: | 0.076 |
Clearance (CL): | 1.55 | Half-life (T1/2): | 0.865 |
hERG Blockers: | 0.423 | Human Hepatotoxicity (H-HT): | 0.37 |
Drug-inuced Liver Injury (DILI): | 0.163 | AMES Toxicity: | 0.252 |
Rat Oral Acute Toxicity: | 0.035 | Maximum Recommended Daily Dose: | 0.009 |
Skin Sensitization: | 0.947 | Carcinogencity: | 0.039 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.012 |
Respiratory Toxicity: | 0.076 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002582 | 0.396 | D0TC7C | 0.460 | ||||
ENC001546 | 0.379 | D0I9HF | 0.441 | ||||
ENC002201 | 0.368 | D0KN2M | 0.303 | ||||
ENC001416 | 0.367 | D0Z2LG | 0.303 | ||||
ENC001567 | 0.358 | D09LBS | 0.303 | ||||
ENC001625 | 0.350 | D0H0SJ | 0.291 | ||||
ENC001560 | 0.344 | D04RYU | 0.286 | ||||
ENC004073 | 0.337 | D0AD5C | 0.283 | ||||
ENC002950 | 0.333 | D01TNW | 0.281 | ||||
ENC001848 | 0.331 | D09NIB | 0.281 |